MedTrace Logo

REduced Frequency ImmuNE Checkpoint Inhibition in Cancers

NCT04913025 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-09-21

No results posted yet for this study

Summary

The REFINE trial aims to asses whether giving an immunotherapy drug less-often to patients with advanced cancer, results in fewer side effects whilst continuing to be an effective treatment. The question will be assessed in different tumour types by means of different cohorts within an overarching trial protocol.

Conditions

Interventions

DRUG

Nivolumab

60-minute IV infusion, as a flat dose of 480mg

DRUG

Pembrolizumab

60-minute IV infusion, as a flat dose of 400mg

Sponsors & Collaborators

  • JP Moulton Charitable Foundation

    collaborator OTHER

  • University College, London

    lead OTHER

Principal Investigators

  • Duncan Gilbert · MRC CTU at UCL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-26
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04913025 on ClinicalTrials.gov